Evidence map›Paper›PMID 24710956›Full record

ArticleClinical & experimental metastasis2014

FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.

Timothy G Whitsett, Shannon P Fortin Ensign, Harshil D Dhruv, Landon J Inge, Paul Kurywchak, Kerri K Wolf, Janine LoBello, Christopher B Kingsley, Jeffrey W Allen, Glen J Weiss and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & experimental metastasis, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Timothy G WhitsettCancer and Cell Biology Division, The Translational Genomics Research Institute (TGen), 445 N. Fifth St., Suite 400, Phoenix, AZ, 85004, USA, twhitsett@tgen.org.
Shannon P Fortin Ensign
Harshil D Dhruv
Landon J Inge
Paul Kurywchak
Kerri K Wolf
Janine LoBello
Christopher B Kingsley
Jeffrey W Allen
Glen J Weiss
Nhan L Tran
Translational Genomics Research Institute · USCancer Treatment Centers of America · USSt. Joseph's Hospital and Medical Center · USUniversity of Arizona · US

Funding

Targeting the Fn14-Rac1 signaling pathway in invasive gliomasR01CA130940 · NCI · TRANSLATIONAL GENOMICS RESEARCH INST · PI TRAN, NHAN L · 2008 to 2012
$1.5M
NCI NIH HHS R01 CA130940
6 · The paper itself

Abstract

The five-year survival rate in advanced non-small cell lung cancer (NSCLC) remains below ten percent. The invasive and metastatic nature of NSCLC tumor cells contributes to the high mortality rate, and as such the mechanisms that govern NSCLC metastasis is an active area of investigation. Two surface receptors that influence NSCLC invasion and metastasis are the hepatocyte growth factor receptor (HGFR/MET) and fibroblast growth factor-inducible 14 (FN14). MET protein is over-expressed in NSCLC tumors and associated with poor clinical outcome and metastasis. FN14 protein is also elevated in NSCLC tumors and positively correlates with tumor cell migration and invasion. In this report, we show that MET and FN14 protein expressions are significantly correlated in human primary NSCLC tumors, and the protein levels of MET and FN14 are elevated in metastatic lesions relative to patient-matched primary tumors. In vitro, HGF/MET activation significantly enhances FN14 mRNA and protein expression. Importantly, depletion of FN14 is sufficient to inhibit MET-driven NSCLC tumor cell migration and invasion in vitro. This work suggests that MET and FN14 protein expressions are associated with the invasive and metastatic potential of NSCLC. Receptor-targeted therapeutics for both MET and FN14 are in clinical development, the use of which may mitigate the metastatic potential of NSCLC.

Indexed as

Neoplasm InvasivenessAnimalsBase SequenceCarcinoma, Non-Small-Cell LungDisease Models, AnimalDNA PrimersHumansLung NeoplasmsMiceProto-Oncogene Proteins c-metReal-Time Polymerase Chain ReactionReceptors, Tumor Necrosis FactorRNA, MessengerTWEAK ReceptorDNA PrimersMET protein, humanProto-Oncogene Proteins c-metReceptors, Tumor Necrosis FactorRNA, MessengerTNFRSF12A protein, humanTnfrsf12a protein, mouseTWEAK Receptor

Identifiers

PMID24710956
OpenAlexW2023723007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.